Osteoporosis is characterized by low bone mass and structural weakness, resulting in a high risk of fracture.
Introduction
Since bone is a major tissue that provides internal skeletal support, debilitating bone diseases, including osteoporosis, osteopetrosis, osteogenesis imperfecta and Paget's disease, are serious dangers during the remaining life time. 1 In particular, over 200 million people worldwide suffer from osteoporosis, one of the common skeletal disorders. 2, 3 Osteoporosis is characterized by low bone mass and bone mineral density (BMD), resulting in an increase of fracture risk. 4 Although various reasons could induce osteoporosis, estrogen deciency is known to disrupt the equilibrium of bone remodeling. 2 A number of recent studies have demonstrated that estrogen plays roles as a regulator of bone turnover and population of osteoclasts. 5 Therefore, osteoporosis is highly distributed in post-menopausal women who have stopped having ability to produce estrogen. 6 For that reason, hormone replacement therapy (HRT) is primarily used to treat postmenopausal osteoporosis. However, increase of cancer risk by long-term use of HRT is concern in osteoporotic patients. 7 Prescribed bisphosphonate to prevent bone loss in postmenopausal women is reported to induce atrial brillation and osteonecrosis of the jaw. 8, 9 Thus approach to nd alternative treatment of osteoporosis with no adverse effects is desirable.
Osteo-F is a newly developed herbal formula consisted of the fruit of Schizandra chinensis, Lycium chinensis and radix of Eucommia ulmoides based on the classic book. According to the Korean traditional literature, S. chinensis, L. chinensis and E. ulmoides have been used for treating bone disease.
10 Additionally, studies regarding on their pharmacological relevancies were recently published. In previous study, S. chinensis exhibited ameliorative effect on osteoporosis in ovariectomized (OVX) mice by increasing estrogen receptor-a and -b.
11 L. chinensis exerted an inhibition of osteoclast formation. 12 The bone remodeling-related factors, Osterix, runt-related transcription factor 2 (Runx2), receptor activator of nuclear factor kappa-B ligand (RANKL) and osteoprotegerin (OPG) were regulated by E. ulmoides in SaOS-2 osteoblast cells.
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Based on previous evidences, we combined a new formula to improve osteoporosis. In this study, the effects of Osteo-F on osteoporosis were determined to analyze the bone mineral content (BMC) and BMD in OVX mice. To understand its mechanism of actions on bone remodeling, the expressions of Runx2 and Osterix in SaOS-2 cells were further investigated.
Experimental

Preparation of Osteo-F
The dried fruit of S. chinensis and L. chinensis, and the radix of E. ulmoides were obtained from Jung-do Herb (Seoul, Korea). Each 200 g of S. chinensis and L. chinensis, and E. ulmoides were extracted twice with 2 L of distilled water, respectively, for 2 h under reux at 100 C. Then the extracts were evaporated using BÜCHI Rotavapor R-220 (BÜCHI Labortechnik, Switzerland) and freeze-dried using lyophilizer (Ilshin Biobase, Korea). The nal yields of each herb were 35%, 31.8% and 10.1%, respectively. Each voucher specimens (SC-W100, LC-W100 and EU-W100) were deposited at our laboratory. Osteo-F consists of S. chinensis, L. chinensis and E. ulmoides according to the dilution ratio 2 : 1 : 1, respectively. For the treatment, 60 mg S. chinensis, 30 mg L. chinensis and 10 mg E. ulmoides extract powders were mixed and dissolved in 1 mL distilled water (nally prepared 100 mg mL À1 Osteo-F), considered on the nal yields of each extract.
The quality evaluation of S. chinensis, L. chinensis and E. ulmoides was performed with three reference compounds of schizandrin, betaine and geniposidic acid, respectively, by highperformance liquid chromatography diode array detector (HPLC-DAD) on an Agilent Series 1100 HPLC system. Chromatographic separation was achieved using the Atlantis HILIC silica (4.6 Â 150 mm, 5 mm). The eluent for schizandrin, betaine and geniposidic acid consisted of 30 mM ammonium acetate and acetonitrile at a ow rate of 1.0 mL min À1 . The detection wavelength was 220 nm at 30 C. The peaks of schizandrin, betaine and geniposidic acid were synchronized with their standards (Fig. 1 ). The concentrations of schizandrin, betaine and geniposidic acid were 273.03 mg mL À1 (1.82%), 360.32 mg mL À1 (1.44%) and 19.56 mg mL À1 (0.07%), respectively.
Mice
ICR female mice aged 6 weeks were purchased from RAONBIO Inc. (Yongin, Korea). Mice were maintained in an air-conditioned room and a 12 h light-dark cycle with freely available of food and water. All experiments were conducted according to the guidelines of the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by
Committee on Care and Use of Laboratory Animals of the Kyung Hee University (KHUASP(SE)-15-093).
Induction of ovariectomy-induced osteoporosis
Aer 1 week of adaption, the mice were randomly divided into six groups (n ¼ 7); Sham, OVX, Ca (calcium chloride-treated group), OF1, OF10 and OF100 (Osteo-F-treated groups at the doses of 1, 10 and 100 mg per kg per day, respectively). All mice except Sham group were OVX and seven mice in Sham group were sham-operated. To recover and induce osteoporosis, mice were maintained for 7 weeks. Aer that, Sham and OVX groups were treated with the vehicle (PBS containing 1% DMSO). 150 mg kg À1 of calcium chloride (Sigma, MO, USA) was orally administrated to Ca group as positive control. And Osteo-F was orally treated ve times per week during 6 weeks. The mice were sacriced aer blood collection by cardiac puncture. The both side of femurs were obtained to analyze the BMC, BMD and bone histology.
Bone histology
The right femurs were xed in 10% neutralized formalin for 18 h and demineralized with 0.1 M ethylene diamine tetraacetic acid aqueous solution for 1 month. Aer demineralization, femur samples were dehydrated by ethanol and xylene. Paraffinembedded femur samples were sagittal sectioned into glass slides. The slides were stained with hematoxylin and eosin. Histological changes were monitored under a light microscope using the Leica Application Suite (LAS; Leica Microsystems, Buffalo Grove, IL, USA). Digital images were taken at a magnication of Â40.
Measurement of BMC and BMD
The le femurs were stored in 10% neutralized formalin until use. The levels of BMC and BMD of the le femurs were determined by dual-energy X-ray absorptiometry with an InAlyzer instrument (MEDIKORS, Seoul, Korea).
Serum analysis
Collected blood samples were centrifuged at 14 000 rpm for 30 min to obtain serum. The serum levels of calcium and magnesium were estimated by using commercial ELISA kit (Adipogen, Shizuoka, Japan) according to the manufacturers' instructions. The optical density was read at 570 nm and 660 nm using a microplate reading instrument (BioTek, PA, USA).
Cell culture and proliferation analysis
SaOS-2 cells (human osteoblastic cell line) were maintained in Dulbecco's modied minimal essential medium (DMEM; Gibco, Grand Island, NY, USA) supplemented with 1% penicillin and 10% heat-inactivated fetal bovine serum (FBS) at 37 C in an atmosphere containing 5% CO 2 that 95% humidity.
The culture medium was changed every 3-4 day. The cells were seeded into 96-well plates at a density of 1 Â 10 6 cells per well. Aer 24 h, the cells were treated with culture medium containing different concentrations of Osteo-F extract (1, 10 and 100 mg mL À1 ) for 24 h. Then, 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium (MTT) solution (2 mg mL
À1
) was added into each well and cultured for 2 h at 37 C. Aerwards, MTT medium was discarded and DMSO was added. The absorbance at 570 nm was measured. The experiments were performed in triplicate.
Western blotting analysis
RIPA buffer (50 mM Tris-HCl (pH 7.4), 1% Nonidet P-40, 0.5% sodium deoxycholate, 150 mM NaCl) containing protease inhibitors (Roche, Hoffmann, USA) was used for cell protein extraction. The protein concentration was determined using the Bradford protein assay. 20 mg of protein was denatured with sodium dodecylsulfate buffer, then electrotransferred onto a PVDF membrane (Bio-Rad, Hercules, CA, USA). Primary antibody (diluted 1 : 1000 in 3% bovine serum albumin; Cell Signaling, USA) was then added to the membrane. Secondary antibodies (Santa Cruz, CA, USA) were incubated for 2 h at RT. The membranes were then visualized using an enhanced chemiluminescence detection reagent (Amersham Pharmacia, Piscataway, NJ, USA).
Statistical analysis
Signicance was determined by one-way analysis of variance (ANOVA) and Dunnett's multiple comparison tests. In all analyses, p < 0.05 was taken to indicate statistical signicance.
Results and discussion
The maintenance of bone homeostasis is controlled by constant replenishment as known as bone remodeling. 14 The two equal, opposite and balanced forces of bone formation by osteoblasts and bone resorption by osteoclasts regulate bone equilibrium.
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Interaction of bone-forming cells and bone-resorbing cells occurs on the bone surface during growth of bone. 16 For that reason, imbalance of bone metabolism leads to disruption of bone remodeling process. 17 Predominant bone resorption by osteoclast activation rather than osteoblast-mediated bone formation in osteoporosis nally leads to loss of bone mass.
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The clinically osteoporotic patient has signicant decreased levels of BMD and BMC. BMD is well known as a hallmark of diagnosis for bone structural deterioration. In addition to BMD, BMC is a one of the primary standards to analyze mechanical strength. 19 The recovery of bone parameters, BMD and BMC, is strongly associated with loss of bone.
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In this study, OVX-induced osteoporotic mice showed decreases of femur BMC and BMD compared to Sham group. Ca treatment signicantly increased the both of BMC and BMD.
Similar to result from Ca group, there was signicant increment of BMC level in 100 mg kg À1 Osteo-F-treated femur. The decreased BMD was markedly recovered in OF10 and OF100 groups (Fig. 3) . In addition, the hyperplasia of growth plate was appeared in osteoporosis-like bone in OVX mice. Administration of Ca suppressed the growth plate thickness compared to OVX group. Increases of growth plate thickness were ameliorated by Osteo-F administration, indicating that Osteo-F attenuated hyperplasia of growth plate (Fig. 2) . Furthermore, calcium concentration in serum as bone turnover marker was signi-cantly decreased by OVX surgery. However, administration of 1, 10 and 100 mg kg À1 Osteo-F markedly increased the calcium levels in a dose-dependent manner. Especially, the serum of calcium level was nearly recovered to normal range in 100 mg kg À1 Osteo-F-treated group (Fig. 4) , while the level of magnesium was not changed by Osteo-F (data not shown). These results suggest that Osteo-F, newly developed formula, is effective on bone formation by increase of serum calcium levels and has anti-osteoporotic effect in OVX mice.
To clarify the mechanisms of Osteo-F on osteoporosis, osteoblast differentiation-related factors such as Runx2 and Fig. 3 The effects of Osteo-F on bone mineral content (BMC) and bone mineral density (BMD). Results are presented as mean AE S.D. ### indicate that the mean differs significantly between the Sham group and the OVX group (p < 0.001). *, ** and *** indicate that the mean differs significantly between the OF or Ca group and the OVX group (p < 0.05, p < 0.01 and p < 0.001, respectively). Osterix were determined in osteoblast like SaOS-2 cells. Two transcriptional factors, Runx2 and Osterix, have been reported to be essential for osteoblast differentiation and maturation from pre-osteoblasts. 21 Because bone formation depends on differentiation of osteoblast (bone-forming cells), the expressions of Runx2 and Osterix are regarded as osteogenic transcriptional factors for skeletal development. 22, 23 The expression level of Runx2 protein was signicantly increased by 100 mg mL À1 Osteo-F treatment in SaOS-2 osteoblast cells. Similarly, 10
and 100 mg mL À1 Osteo-F treatment up-regulated the expression of Osterix protein, compared to non-treated cells (Fig. 5) . Especially, 100 mg mL À1 Osteo-F treatment signicantly increased the both of Osterix and Runx2. All concentrations of Osteo-F exerted equivalent effects on SaOS-2 cell viability. Osteo-F was not cytotoxic to SaOS-2 cell (data not shown). Osteo-F could differentiate from pre-osteoblasts to mature osteoblasts by up-regulating Runx2 and Osterix demonstrating the potential mechanism of action of Osteo-F on bone remodeling, especially osteoblast differentiation.
Conclusions
Osteo-F, a newly combined formula, has anti-osteoporotic effects in OVX mice. The levels of BMC and BMD were ameliorated, and histological changes of femur were recovered by Osteo-F treatment. In addition, Osteo-F showed bone remodeling by promoting osteoblast differentiation via up-regulation of Runx2 and Osterix. Taken together, Osteo-F could be one of the alternative materials for the improvement of osteoporosis.
